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ABSTRACT
Genetic factors contribute to more than 40% of prostate cancer risk, and mutations in BRCA1 and BRCA2
are well-established risk factors. By using target capture-based deep sequencing to identify potential
pathogenic germline mutations, followed by Sanger sequencing to determine the loci of the mutations,
we identified a novel pathogenic BRCA2 mutation caused by a cytosine-to-guanine base substitution
at position 4211, resulting in protein truncation (p.Ser1404Ter), which was confirmed by
immunohistochemistry. Analysis of peripheral blood also identified benign polymorphisms in BRCA2
(c.7397T>C, p.Val2466Ala) and SRD5A2 (c.87G>C, p.Lys29Asn). Analysis of tumor tissues revealed seven
somatic mutations in prostate tumor tissue and nine somatic mutations in esophageal squamous
carcinoma tissue (single nucleotide polymorphisms, insertions, and deletions). Five-year follow-up results
indicate that ADT combined with radiotherapy successfully treated the prostate cancer. To our knowledge,
we are the first to report the germline BRCA2 mutation c.4211C>G (p.Ser1404Ter) in prostate cancer.
Combined ADT and radiotherapy may be effective in treating other patients with prostate cancer caused
by this or similar mutations.
KEYWORDS
BRCA2; prostate cancer;
radiotherapy; androgen
deprivation therapy
Introduction
Prostate cancer (PCa) is one of the most common cancers
affecting men, especially in developed countries. For example,
in the United States it is estimated that there will be 161,360
new PCa cases in 2017, and 26,730 men will die from PCa.1
Other than advanced age, family history is the strongest risk
factor for PCa,2 with approximately 42% of the risk for this dis-
ease attributed to genetic factors.3 Compared with PCa caused
by somatic mutations, hereditary PCa has earlier onset and
higher rates of metastasis and mortality.4 Previous studies have
identified more than 70 PCa susceptible loci, which account for
approximately 30% of the familial PCa risk.5 Mutations in the
tumor suppressor genes BRCA1 and BRCA2 are well-known
genetic risk factors for this cancer.
BRCA1 and BRCA2mutations are associatedwith an increased
risk for many cancers including breast, ovarian, pancreatic, stom-
ach, laryngeal, and fallopian tube cancer, as well as PCa.6 The
increased cancer risk in carriers of the BRCA1/BRCA2mutations
is predominantly in breast cancer and ovarian cancer for women7
and PCa for men.8 Germline BRCA2 and BRCA1 mutations are
present in 1.2% and 0.44% of PCa tumors, respectively.9 Com-
pared with the general population, the relative risk of PCa is 3.8
for carriers of BRCA1mutations up to 65 years of age10 and 5 to 7
for carriers of BRCA2 mutations.11,12 Male BRCA mutation
carriers with localized PCa are at substantially higher risk of dying
from PCa than their non-mutation–carrying counterparts.13
Moreover, BRCA2 contributes to early onset, with 1.2% patients
younger than 65 years old carrying germline BRCA2 mutations.9
BRCA1/2 mutations are also associated with higher Gleason
scores,14 and germline BRCA1/2 mutations confer a more aggres-
sive phenotype with a higher probability of nodal involvement,
distant metastasis, and shorter survival.15
Tumors in BRCA mutation carriers that have defects in
homologous recombination can be treated with radiotherapy, cis-
platin, anthracyclines, or poly(ADP-ribose) polymerase inhibi-
tors.16,17 In addition, radical local therapy (e.g., radical
prostatectomy or radiotherapy) can be effective when performed
early for PCa with BRCA2mutations.18 For metastatic castration-
resistant PCa with biallelic inactivation of BRCA2, chemotherapy
with platinum agents has been suggested.19 In addition, Bryant
et al.16 reported that poly(ADP-ribose) polymerase inhibitors are
efficacious in cancers with homologous recombination defects in
tumors deficient in BRCA1 and BRCA2 but not in tumors with
functional BRCA1 or BRCA2 proteins. However, optimal treat-
ment strategies for specific mutations are unclear. Here we report
a patient with locally advanced PCa carrying a novel germline
BRCA2mutation. The patient was treated with androgen depriva-
tion therapy (ADT) combined with radiotherapy, and serum
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prostate-specific antigen (PSA) levels were within the normal
range for almost 4 years, even after stopping ADT.
Results
Case presentation
In May 2011, a 46-year-old Chinese man with dysuria lasting
for 6 months was referred to Daping Hospital of the Third Mil-
itary Medical University. Results of digital rectal examination
revealed a hard and enlarged prostate with irregularities. Labo-
ratory test results showed elevated serum levels of total PSA
(56.39 ng/ml) and free PSA (10.30 ng/ml). Pelvic magnetic res-
onance imaging (MRI) scans showed lesions in the peripheral
zone of the prostate with low-intensity signal (3.4 £ 4.6 cm)
and multiple enlarged pelvic lymph nodes with high-intensity
signal (largest node, approximately 1.5 £ 2.2 cm) on T2-
weighted imaging (Fig. 1A). Ultrasound-guided transrectal nee-
dle biopsies obtained June 23, 2011 confirmed prostate adeno-
carcinoma (Gleason score 5 C 4). Immunohistochemistry
results showed positive staining for Ki-67, p504S, and PSA, and
negative results for p63 and 34bE2. Results of positron emis-
sion tomography (PET)-computed tomography (CT) showed a
high level of asymmetrical 18F fluorodeoxyglucose (FDG)
uptake in the prostate along the left side, confirming metastasis
in pelvic lymph nodes. The patient had no relevant family his-
tory, and his parents had died of unknown causes.
To treat this locally advanced PCa, ADT was initiated
immediately with goserelin injections and oral bicalutamide,
and testosterone and total/free PSA levels were monitored
during and after treatment (Fig. 2). Serum PSA levels were
maintained within the normal range for approximately
17 months, but total PSA (9.36 ng/ml) was found to be ele-
vated on November 9, 2012. Results of MRI performed on
November 26, 2012 (Fig. 1B) showed that the pelvic lymph
nodes and tumor had shrunk (2.1 £ 2.7 cm), presumably
as a result of ADT. Local radiotherapy (66 Gy/30 F or
2.2 Gy/F) was carried out November 28, 2012. MRI results
on January 4, 2013 showed the tumor had shrunk further
(1.6 £ 2.4 cm) (Fig. 1C). To treat lymph nodes, pelvic
radiotherapy (13.2 Gy/6 F or 2.2 Gy/F) was continued until
January 23, 2013. Because total and free PSA levels were
still within the normal range, ADT was discontinued
November 13, 2013, and on follow-up MRI on February 3,
2016, the prostate tumor was barely detectable (Fig. 1D).
The prostate tumor appeared to be under control for 4 years
without further intervention (Fig. 1E). In addition, serum
testosterone level had returned to normal, and the patient’s
libido and sexual activity recovered completely.
In May 2015, the patient was again referred to our hospital
because of dysphagia lasting for a month. Gastroscopy revealed an
esophageal mass (29 £ 34 cm) far from the incisors, and biopsy
results suggested esophageal squamous carcinoma. PET-CT
images showed a high level of asymmetrical FDG uptake in the
Figure 1. MRI scans of the patient before and after treatment for prostate cancer. (A–E) T1-weighted image (T1WI) and T2-weighted image (T2WI), as well as the sagittal
view and lymph node images from T2WI from June 21, 2011 to April 13, 2017. Red arrows indicate the tumor in the prostate and lymph node metastasis.
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esophagus only. On May 11, 2015, the patient underwent esoph-
ageal resection and thoracoscopic lymph node resection.
Identification of pathogenic mutation
To identify potential pathogenic mutations, we screened a panel
of seven genes (BRCA2, CHEK2, ELAC2, HSD17B3, HSD3B2,
RNASEL, and SRD5A2) using the patient’s peripheral blood and
identified a novel germline BRCA2 mutation: Ser1404Ter caused
by a C>G point mutation at position 4211 (Fig. 3A). We also
identified two germline mutations in BRCA2 (c.7397T>C, p.
Val2466Ala) and SRD5A2 (c.87G>C, p.Lys29Asn) that resulted
in benign polymorphisms (data not shown). In addition, somatic
mutations were identified by whole exome sequencing. The fol-
lowing seven somatic single nucleotide polymorphism/indel
mutations were identified in PCa tumor tissue: TP53
(c.1049T>C, p.L350P), PIK3CB (c.2527G>C, p.A843P), MLL
(c.2806T>A, p.S936T), PTCH1 (c.2075>A, p.V692E), and TERT
(c.-58-u5148C>A; c.-58-u3620G>A; c.-58-u1324T>C). The fol-
lowing nine somatic single nucleotide polymorphism/indel muta-
tions were identified in esophageal squamous carcinoma tissue:
TP53 (c.743G>A, p.R248Q; c.713G>C, p.C238S), PIK3CA
(c.1636C>A, p.Q546K), PTPRD (c.5083G>A, p.E1695K), MLL3
(c.4093-2A>G; c.10249C>A, p.Q3417K), OR4C6 (c.541C>A, p.
Q181K), MSH6 (c.124C>G, p.P42A), and TMPRSS2
(c.589G>A, p.V197M).
Expression and subcellular location of the truncated
BRCA2 protein
To determine whether the patient’s BRCA2 mutation resulted in a
truncated protein, we analyzed prostate and esophageal tumor tis-
sues by immunohistochemistry. Using the BRCA2 C-terminal
antibody, fewer BRCA2-positive cells were detected in the patient’s
prostate and esophagus tumor tissues compared with control tis-
sues (Fig. 4A). However, using the BRCA2 N-terminal antibody,
the number of BRCA2-positive cells in the tumor tissues was com-
parable between the patient and control, confirming the presence
of a truncated protein (Fig. 3B). Levels of full-length BRCA2 in the
patient’s tumor tissues were considerably lower than those of con-
trol tissues, presumably due to the heterozygosity of the BRCA2
mutation expressing the truncated protein. Truncated BRCA2
protein was detected primarily in the cytoplasm, whereas full-
length BRCA2 protein was detected primarily in the nucleus
(Fig. 4A). Furthermore, by using western blot, we identified the
truncated BRCA2 protein at around 170 kDa (Fig. 4B).
Discussion
To the best of our knowledge, this is the first description of PCa
caused by a germline BRCA2 mutation in a Chinese patient,
Figure 3. (A) BRCA2 mutation in patient with prostate cancer and esophageal squamous carcinoma. (B) Diagram of wild type (WT) (ref. 37) and mutant BRCA2 proteins, as
predicted from cDNA and genomic sequencing. NLS, nuclear localization signal; TR2, RAD51-binding domain.
Figure 2. Treatment regimen and laboratory test results during and after treat-
ment for prostate cancer. (A) Therapeutic schedule. (B) Serum levels of TPSA, FPSA,
and testosterone during and after treatment. FPSA, free prostate-specific antigen;
TPSA, total prostate-specific antigen. ADT: Androgen deprivation therapy.
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and the first report of the BRCA mutation c.4211C>G, which
results in a truncated protein (p.Ser1404Ter). We also demon-
strated that PCa associated with this mutation is sensitive to
ADT combined with radiotherapy.
BRCA2 encodes a 3418-amino acid protein containing
eight BRC repeats, a DNA-binding domain, and a nuclear
localization signal.20 As a component of the double-strand
break (DSB) repair machinery, BRCA2 interacts with
RAD51 through the BRC repeats and the RAD51-binding
domain at its C-terminus (residues 3196–3232).21,22 The
mutation identified in this report introduces a premature
stop codon, resulting in a truncated 1403-amino acid pro-
tein (Fig. 3B). Analysis of previously reported BRCA2 muta-
tions suggests that truncation producing a protein smaller
than 3308 amino acids severely affects protein function.23
The truncated BRAC2 identified in our patient contains
only two of the eight BRC repeats and lacks the essential
C-terminal domain. Loss of the nuclear localization signal
(Fig. 3B) may account for cytoplasmic localization of the
truncated BRAC2. Based on these observations, we conclude
that this mutation leads to loss of function.
Previous studies have described BRCA2 mutations associated
with esophagus cancer, including the mutations c.203G>A,24
c.10462A>G (p.Ile3412Val), c.8415G>T (p.Lys2729Asn),25 and
c.10204A>T (p.Lys3326Ter).26,27 The mutation identified in this
case (C.4211C>G, p.Ser1404Ter) also appears increase the risk of
esophageal cancer, suggesting that special attention should be paid
to patients with germline mutations of BRCA2 during examina-
tion of the upper aero-digestive tract. This mutation may also
increase the risk of other cancers, given the important role of
BRCA2 in DNA repair.
According to the two-hit hypothesis,28 multiple muta-
tions are necessary to cause cancer. Thus, accumulation of
acquired and uncorrected somatic mutations is expected in
individuals with germline BRCA2 mutations. Indeed, whole
exome sequencing revealed multiple somatic mutations in
our patient’s prostate and esophageal tumor tissues. Misre-
pair or inefficient repair of DSBs can lead to genetic insta-
bility and ultimately carcinogenesis.29,30 Indeed, BRCA2 has
been identified as one of the most common mutations
among the 63 pathogenic germline mutations (PPGMs) in
cancers.31 In our patient, haploinsufficiency of BRCA2 and
inefficient DSB repair is likely to be the pathologic mecha-
nism underlying the development of cancer. Consistent
with the finding that most cancer-causing somatic muta-
tions are associated with chromatin remodeling and DNA
repair,32 we found that both tumors in our patient had
mutations in the tumor protein p53 (TP53), phosphatidyli-
nositol-4,5-bisphosphate 3-kinase (PIK3C), and mixed line-
age leukemia (MLL) pathways. However, we do not have
direct evidence linking these somatic mutations to the
BRCA2 truncation.
Most PCa patients carrying BRCA2 mutations are
treated with radical local therapy with or without adjuvant
ADT.32 Here we assessed the effect of initial ADT and sub-
sequent radiotherapy on PCa associated with a BRCA2
mutation. The initial ADT appeared to be effective, as evi-
denced by decreased PSA level and reduced tumor size,
Figure 4. Immunohistochemistry and western blot analysis of tumor tissues. (A) The patient’s prostate and esophageal tumor tissues were stained with antibodies against
BRCA (C-terminus and N-terminus) and compared with the corresponding control tumor tissues. HE, hematoxylin and eosin. (B) The patient’s esophageal tumor tissues
kept in liquid nitrogen were collected, lysed and then analyzed with western blot assays with specific antibodies against BRCA2 N-terminus.
Table 1. The levels of TPSA, FPSA and testosterone of the patient during the
treatment.
Time TPSA (ng/ml) FPSA (ng/ml) Testosterone (nmol/L)
2011/5/21 56.39 10.3
2011/7/27 8.51 0.88
2011/8/31 3.69 0.28
2011/9/1 0.868
2011/10/26 2.72 0.25
2011/12/14 4.81 0.19
2012/1/18 2.52 0.31
2012/4/18 3.83 0.6 0.174
2012/9/16 7.81 1.32
2012/11/9 9.36 1.84 0.486
2012/11/26 9.28 1.17 0.66
2013/1/13 1.96 0.24 0.208
2013/5/2 0.31 0.07
2013/11/13 0.15 0.03
2014/4/23 0.13 0.03
2014/11/12 0.1 0.02
2015/3/25 0.1 0.02
2015/6/10 0.11 0.03 5.625
2016/2/3 0.14 0.02 7.639
2016/5/18 0.14 0.02 9.201
2016/7/20 0.17 0.02 9.41
2016/11/9 0.29 0.02 11.736
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suggesting an ADT-sensitive tumor. However, the tumor
become ADT-resistant, as evidenced by an increase in total
PSA level (9.36 ng/ml); therefore, radiotherapy was
administered.
Radiation therapy, which is used to treat many solid tumors,
directly induces DSBs and indirectly induces other types of
DNA damage, in part by producing reactive oxygen species.
Signals from the damaged DNA trigger cell cycle arrest33 and
activate the DNA repair machinery. Although unrepaired DNA
damage in normal cells can lead to tumorigenesis, irreparable
DNA damage in cancer cells leads to apoptosis.34 Because of its
role in DNA repair, BRCA2 plays pivotal roles in both tumori-
genesis and radiotherapy. BRCA2 haploinsufficiency increases
sensitivity to DNA-damaging agents, as evidenced by multiple
somatic mutations in the patient’s prostate and esophagus
tumors. On the other hand, cancer cells expressing truncated
BRCA2 are expected to be more responsive to radiotherapy.
Polymorphisms in genes such as XRCC3 and RAD51 are also
associated with radiosensitivity,29 but whether the SRD5A2
mutation (c.87G>C, p.Lys29Asn) identified in our patient
plays a role in radiosensitivity is unclear. Nevertheless, the
treatment outcome of our patient indicates that ADT combined
with radiotherapy was effective for PCa caused by this BRCA2
germline mutation.
In conclusion, we believe we are the first to describe this
germline mutation of BRCA2 (c.4211C>G, p.Ser1404Ter) in a
patient with PCa, which was effectively treated with ADT and
radiotherapy.
Materials and methods
All procedures involving human participants were carried
out in accordance with the ethical standards of the institu-
tional research committee and with the 1964 Helsinki Dec-
laration and its later amendments or comparable ethical
standards. The Daping Hospital of Third Military Medical
University waived institutional review board approval for
the study; however, written informed consent for the use of
medical records and related images was obtained from the
patient.
Identification of patient mutations
Germline DNA was extracted from the patient’s leuko-
cytes, and tumor DNA was extracted from PCa and esoph-
ageal squamous carcinoma tissues using the QIAamp DNA
Micro Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. In addition, total DNA puri-
fied from the patient’s peripheral blood was analyzed by
target capture-based deep sequencing (BGI Health, China)
to identify potential mutations in the following genes:
BRCA2, CHEK2, ELAC2, HSD17B3, HSD3B2, RNASEL,
and SRD5A2. The potential mutations were analyzed by
Sanger sequencing to determine the loci and then com-
pared with reference sequences in GenBank (http://www.
ncbi.nlm.nih.gov/genbank/) using Mutation Surveyor version
2.51 (SoftGenetics LLC). Whole exome sequencing of the
tumor DNA was performed by Geneplus-Beijing Institute
(Beijing, China).
Immunohistochemistry
Tissue biopsies (greatest dimension, 1.5 mm) were taken from
clinical specimens of the patient and two controls lacking the
identified mutation (another patient with PCa and a patient
with esophagus cancer). As previously described,35,36 the paraf-
fin-embedded tissues were sectioned (4 mm thick), mounted
on glass slides, and baked at 60C for 6 h. After deparaffiniza-
tion with xylene, the sections were rehydrated in graded etha-
nol and 3% hydrogen peroxide to block endogenous peroxidase
activity. Goat serum (ZSGB-BIO, China) was used to block
nonspecific interactions before incubating the sections at 4C
with specific primary antibodies against the BRCA2 C-terminus
(amino acids 2587–2601, Abcam ab53887, Cambridge, MA,
USA) and BRCA2 N-terminus (amino acids 100–150 amino
acids, Proteintech 19791-1-ap, Rosemont, IL, USA). After incu-
bation with secondary antibody conjugated to streptavidin-bio-
tin-horseradish peroxidase complex, the tissue sections were
counterstained with hematoxylin and eosin, dehydrated, and
covered with coverslips. Images of the slides were obtained
with an Olympus CCD camera (Tokyo, Japan) connected to a
Nikon Eclipse Ti-S inverted microscope (Tokyo, Japan) and
captured with NIS-Elements F3.2 imaging software. The images
were assessed by two urological pathologists.
Western blot
The esophageal squamous carcinoma tissues of the patient kept
in liquid nitrogen were collected and lysed in a RIPA buffer
containing a protease inhibitor cocktail tablet and phosphotase
inhibitor cocktail (KeyGEN BioTECH, NanJing, China). 80 ug
of tissue protein were separated by SDS-PAGE and transferred
onto PVDF membrane (PALL, NY). After 1 h of incubation in
blocking solution (5% BSA in PBS), primary antibody: BRCA2
N-terminus (amino acids 100–150 amino acids, Proteintech
19791-1-ap, Rosemont, IL, USA) was used to dected the trun-
cated protein.
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